

Cem Akin

List of Publications by Citations

Source: <https://exaly.com/author-pdf/622797/cem-akin-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

99
papers

5,726
citations

36
h-index

75
g-index

127
ext. papers

6,856
ext. citations

5.7
avg, IF

6.03
L-index

#	Paper	IF	Citations
99	Diagnostic criteria and classification of mastocytosis: a consensus proposal. <i>Leukemia Research</i> , 2001 , 25, 603-25	2.7	871
98	The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. <i>Blood</i> , 2002 , 99, 1741-4	2.2	382
97	Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. <i>Blood</i> , 2017 , 129, 1420-1427	2.2	346
96	Mast Cells, Mastocytosis, and Related Disorders. <i>New England Journal of Medicine</i> , 2015 , 373, 163-72	59.2	297
95	A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. <i>Blood</i> , 2004 , 103, 3222-5	2.2	293
94	Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. <i>New England Journal of Medicine</i> , 2016 , 374, 2530-31	59.2	269
93	Mast cell activation syndrome: Proposed diagnostic criteria. <i>Journal of Allergy and Clinical Immunology</i> , 2010 , 126, 1099-104.e4	11.5	212
92	Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. <i>Journal of Allergy and Clinical Immunology</i> , 2016 , 137, 35-45	11.5	209
91	Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. <i>Experimental Hematology</i> , 2003 , 31, 686-92	3.1	191
90	Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. <i>Leukemia Research</i> , 2003 , 27, 635-41	2.7	184
89	Advances in the Classification and Treatment of Mastocytosis: Current Status and Outlook toward the Future. <i>Cancer Research</i> , 2017 , 77, 1261-1270	10.1	162
88	Diagnosis and treatment of systemic mastocytosis: state of the art. <i>British Journal of Haematology</i> , 2003 , 122, 695-717	4.5	157
87	17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells. <i>Blood</i> , 2004 , 103, 1078-84	2.2	135
86	Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3264-74	2.2	111
85	Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019 , 7, 1125-1133.e1	5.4	106
84	Mast cell activation syndromes. <i>Journal of Allergy and Clinical Immunology</i> , 2017 , 140, 349-355	11.5	102
83	Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. <i>Leukemia Research</i> , 2011 , 35, 1143-52	2.7	95

82	How I treat patients with advanced systemic mastocytosis. <i>Blood</i> , 2010 , 116, 5812-7	2.2	91
81	International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. <i>Blood</i> , 2013 , 121, 2393-401	2.2	89
80	Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. <i>World Allergy Organization Journal</i> , 2016 , 9, 7	5.2	86
79	The Mastocytosis Society survey on mast cell disorders: patient experiences and perceptions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014 , 2, 70-6	5.4	79
78	Diagnostic criteria and classification of mastocytosis in 2014. <i>Immunology and Allergy Clinics of North America</i> , 2014 , 34, 207-18	3.3	69
77	Molecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology. <i>Journal of Molecular Diagnostics</i> , 2006 , 8, 412-9	5.1	64
76	Current treatment options in patients with mastocytosis: status in 2015 and future perspectives. <i>European Journal of Haematology</i> , 2015 , 94, 474-90	3.8	52
75	Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1348-1356	4.7	51
74	The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-Analysis, GRADE Assessment, and International Consensus Approach. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021 , 9, 3546-3567	5.4	47
73	Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome. <i>International Archives of Allergy and Immunology</i> , 2019 , 180, 44-51	3.7	46
72	Clonality and molecular pathogenesis of mastocytosis. <i>Acta Haematologica</i> , 2005 , 114, 61-9	2.7	46
71	Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice. <i>Haematologica</i> , 2016 , 101, 1133-1143	6.6	46
70	Treatment strategies in mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , 2014 , 34, 433-47	3.3	43
69	AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management. <i>Journal of Allergy and Clinical Immunology</i> , 2019 , 144, 883-896	11.5	41
68	Risk Factor Analysis of Anaphylactic Reactions in Patients With Systemic Mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017 , 5, 1248-1255	5.4	40
67	Anaphylaxis and mast cell disease: what is the risk?. <i>Current Allergy and Asthma Reports</i> , 2010 , 10, 34-8	5.6	40
66	Mast cells as a unique hematopoietic lineage and cell system: From Paul Ehrlich's visions to precision medicine concepts. <i>Theranostics</i> , 2020 , 10, 10743-10768	12.1	40
65	Mast cell activation disorders. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014 , 2, 252-7.e1; quiz 258	5.4	38

64	Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	36
63	Anaphylaxis after hymenoptera sting: is it venom allergy, a clonal disorder, or both?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015 , 3, 350-5	5.4	36
62	Mast cell activation syndromes presenting as anaphylaxis. <i>Immunology and Allergy Clinics of North America</i> , 2015 , 35, 277-85	3.3	32
61	Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment. <i>Current Allergy and Asthma Reports</i> , 2006 , 6, 282-8	5.6	25
60	Mast cell activation syndrome: Importance of consensus criteria and call for research. <i>Journal of Allergy and Clinical Immunology</i> , 2018 , 142, 1008-1010	11.5	22
59	Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	22
58	Endocrine manifestations of systemic mastocytosis in bone. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2016 , 17, 419-431	10.5	22
57	High serum corticotropin-releasing hormone (CRH) and bone marrow mast cell CRH receptor expression in a mastocytosis patient. <i>Journal of Allergy and Clinical Immunology</i> , 2014 , 134, 1197-9	11.5	20
56	Doctor, I Think I Am Suffering from MCAS: Differential Diagnosis and Separating Facts from Fiction. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019 , 7, 1109-1114	5.4	19
55	Proposed Terminology and Classification of Pre-Malignant Neoplastic Conditions: A Consensus Proposal. <i>EBioMedicine</i> , 2017 , 26, 17-24	8.8	17
54	COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM). <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021 , 9, 2139-2144	5.4	17
53	Venom immunotherapy in patients with clonal mast cell disorders: IgG4 correlates with protection. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020 , 75, 169-177	9.3	17
52	Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphology. <i>Journal of Allergy and Clinical Immunology</i> , 2021 , 147, 1497-1501.e1	11.5	17
51	Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A Consensus Proposal.. <i>HemaSphere</i> , 2021 , 5, e646	0.3	16
50	Idiopathic anaphylaxis yardstick: Practical recommendations for clinical practice. <i>Annals of Allergy, Asthma and Immunology</i> , 2020 , 124, 16-27	3.2	16
49	Risk and management of patients with mastocytosis and MCAS in the SARS-CoV-2 (COVID-19) pandemic: Expert opinions. <i>Journal of Allergy and Clinical Immunology</i> , 2020 , 146, 300-306	11.5	15
48	Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. <i>Journal of Allergy and Clinical Immunology</i> , 2020 , 146, 356-366.e4	11.5	15
47	KIT Inhibitor Midostaurin in Patients with Advanced Systemic Mastocytosis: Results of a Planned Interim Analysis of the Global CPKC412D2201 Trial. <i>Blood</i> , 2012 , 120, 799-799	2.2	15

46	Core-binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I-CBFit). <i>Cancer Medicine</i> , 2018 , 7, 4447-4455	4.8	13
45	Cladribine for mastocytosis: benefits and risks. <i>Blood</i> , 2015 , 126, 931-2	2.2	12
44	Midostaurin (PKC412) Demonstrates a High Rate of Durable Responses in Patients with Advanced Systemic Mastocytosis: Results from the Fully Accrued Global Phase 2 CPKC412D2201 Trial. <i>Blood</i> , 2014 , 124, 636-636	2.2	12
43	Preclinical human models and emerging therapeutics for advanced systemic mastocytosis. <i>Haematologica</i> , 2018 , 103, 1760-1771	6.6	11
42	Management of Mastocytosis in Pregnancy: A Review. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017 , 5, 1217-1223	5.4	10
41	BMS-354825 Is a SRC/ABL Inhibitor with High Nanomolar Activity Against the Kit D816v Mutation, Which Drives Systemic Mastocytosis and Is Imatinib-Resistant.. <i>Blood</i> , 2004 , 104, 797-797	2.2	10
40	Hereditary alpha tryptasemia is not associated with specific clinical phenotypes. <i>Journal of Allergy and Clinical Immunology</i> , 2021 ,	11.5	10
39	COVID-19 infection in patients with mast cell disorders including mastocytosis does not impact mast cell activation symptoms. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021 , 9, 2083-2086	5.4	9
38	The Mastocytosis Society Survey on Mast Cell Disorders: Part 2-Patient Clinical Experiences and Beyond. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019 , 7, 1157-1165.e6	5.4	9
37	Mast Cell Activation: When the Whole Is Greater than the Sum of Its Parts. <i>Medical Clinics of North America</i> , 2020 , 104, 177-187	7	8
36	Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021 , 9, 3918-3928	5.4	8
35	Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021 , 9, 3198-3199	5.4	8
34	New Insights into Clonal Mast Cell Disorders Including Mastocytosis. <i>Immunology and Allergy Clinics of North America</i> , 2018 , 38, 341-350	3.3	7
33	Idiopathic Anaphylaxis: A Form of Mast Cell Activation Syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020 , 8, 1196-1201	5.4	6
32	Hymenoptera-induced anaphylaxis: is it a mast cell driven hematological disorder?. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2017 , 17, 356-362	3.3	6
31	Durable Responses and Improved Quality Of Life With Midostaurin (PKC412) In Advanced Systemic Mastocytosis (SM): Updated Stage 1 Results Of The Global D2201 Trial. <i>Blood</i> , 2013 , 122, 106-106	2.2	6
30	New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1075-1083	1.9	5
29	Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21). <i>Blood Advances</i> , 2021 , 5, 2481-2489	7.8	5

28	Idiopathic Anaphylaxis: a Perplexing Diagnostic Challenge for Allergists. <i>Current Allergy and Asthma Reports</i> , 2021 , 21, 11	5.6	5
27	Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group.. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022 ,	5.4	5
26	Blisters, Vaccines, and Mast Cells: A Difficult Case of Diffuse Cutaneous Mastocytosis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019 , 7, 1370-1372	5.4	4
25	Anaphylaxis and Mast Cell Disorders. <i>Immunology and Allergy Clinics of North America</i> , 2022 , 42, 45-63	3.3	4
24	Allogeneic hematopoietic cell transplantation in systemic mastocytosis: is there a high risk for veno-occlusive disease?. <i>European Journal of Haematology</i> , 2016 , 96, 655-7	3.8	4
23	Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 487-498	5.4	4
22	Diffuse cutaneous mastocytosis with novel somatic KIT mutation K509I and association with tuberous sclerosis. <i>Clinical Case Reports (discontinued)</i> , 2018 , 6, 1834-1840	0.7	4
21	Phase II Study of Dasatinib (SPRYCEL) in Philadelphia Chromosome-Negative Acute and Chronic Myeloid Diseases, Including Systemic Mastocytosis.. <i>Blood</i> , 2007 , 110, 3551-3551	2.2	3
20	Prevalence of mastocytosis and Hymenoptera venom allergy in the United States. <i>Journal of Allergy and Clinical Immunology</i> , 2021 , 148, 1316-1323	11.5	3
19	A Challenge for Allergologist: Application of Allergy Diagnostic Methods in Mast Cell Disorders. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	3
18	The Role of KIT Mutations in Anaphylaxis. <i>Current Allergy and Asthma Reports</i> , 2019 , 19, 31	5.6	2
17	Diagnosis and Treatment of Anaphylaxis in Patients with Mastocytosis. <i>Current Treatment Options in Allergy</i> , 2014 , 1, 247-261	1	2
16	Recent advances in mast cell clonality and anaphylaxis. <i>F1000 Medicine Reports</i> , 2009 , 1,		2
15	Mast Cell Disorders. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016 , 4, 557-8	5.4	2
14	Core-binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure. <i>International Journal of Laboratory Hematology</i> , 2021 , 43, e19-e25	2.5	2
13	Non-hematologic diagnosis of systemic mastocytosis: Collaboration of radiology and pathology. <i>Blood Reviews</i> , 2021 , 45, 100693	11.1	1
12	Personalized Management Strategies in Mast Cell Disorders: ECNM-AIM User's Guide for Daily Clinical Practice.. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022 ,	5.4	1
11	Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study. <i>Orphanet Journal of Rare Diseases</i> , 2021 , 16, 434	4.2	0

10	Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF. <i>Orphanet Journal of Rare Diseases</i> , 2021 , 16, 414	4.2	○
9	Developing a standardized approach for assessing mast cells and eosinophils on tissue biopsies: A Work Group Report of the AAAAI Allergic Skin Diseases Committee. <i>Journal of Allergy and Clinical Immunology</i> , 2021 , 148, 964-983	11.5	○
8	Itching without a rash. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015 , 3, 307-8; quiz 309	5.4	
7	Systemic Mastocytosis with Eosinophilia: A Novel Diagnostic Approach To Distinguish Imatinib-Resistant Kit D816V-Associated Mast Cell Disease from Imatinib-Sensitive FIP1L1/PDGFR-Associated Hypereosinophilic Syndrome.. <i>Blood</i> , 2006 , 108, 2683-2683	2.2	
6	Novel C-KIT Transcripts Identified in Mast Cell Leukemia: An Update of the Full Transcript and Its Distribution.. <i>Blood</i> , 2007 , 110, 2396-2396	2.2	
5	Mastocytosis: Overview of Diagnosis and Classification 2020 , 23-34		
4	Allogeneic Hematopoietic Cell Transplantation Is Effective In Patients With Advanced Systemic Mastocytosis: A Multicenter Retrospective Analysis. <i>Blood</i> , 2013 , 122, 2145-2145	2.2	
3	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2021 , 148, 1343-1344	11.5	
2	Scratching the Itch: Managing Recurrent Pruritic Skin Conditions.. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022 , 10, 882-883	5.4	
1	Reply to "Need to define a subgroup of patients with idiopathic mast cell activation syndrome".. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022 , 10, 1128	5.4	